The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS: A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Fouqueray, Pascale, Pirags, Valdis, Inzucchi, Silvio E., Bailey, Clifford J., Schernthaner, Guntram, Diamant, Michaela, Lebovitz, Harold E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Diabetes Association 2013
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579350/
https://ncbi.nlm.nih.gov/pubmed/23160726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-0453
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak